Literature DB >> 24911474

Sovaldi makes blockbuster history, ignites drug pricing unrest.

Melanie Senior.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24911474     DOI： 10.1038/nbt0614-501

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  FDA approvals usher in the post-interferon era in HCV.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2014-01       Impact factor: 54.908
  1 in total
  4 in total

1.  $1-million price tag set for Glybera gene therapy.

Authors:  Chris Morrison
Journal:  Nat Biotechnol       Date:  2015-03       Impact factor: 54.908

2.  Drugmakers accused of exploiting orphan drug incentives, fueling price problem.

Authors:  Brady Huggett
Journal:  Nat Biotechnol       Date:  2017-04-11       Impact factor: 54.908

3.  DRUG PRICING & CHALLENGES TO HEPATITIS C TREATMENT ACCESS.

Authors:  Brandy Henry
Journal:  J Health Biomed Law       Date:  2018-09

4.  Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future.

Authors:  Winnie de Bruijn; Cristina Ibáñez; Pia Frisk; Hanne Bak Pedersen; Ali Alkan; Patricia Vella Bonanno; Ljiljana S Brkičić; Anna Bucsics; Guillaume Dedet; Jaran Eriksen; Joseph O Fadare; Jurij Fürst; Gisselle Gallego; Isabella P Godói; Augusto A Guerra Júnior; Hakkı Gürsöz; Saira Jan; Jan Jones; Roberta Joppi; Saim Kerman; Ott Laius; Newman Madzikwa; Einar Magnússon; Mojca Maticic; Vanda Markovic-Pekovic; Amos Massele; Olayinka Ogunleye; Aisling O'Leary; Jutta Piessnegger; Catherine Sermet; Steven Simoens; Celda Tiroyakgosi; Ilse Truter; Magnus Thyberg; Kristina Tomekova; Magdalena Wladysiuk; Sotiris Vandoros; Elif H Vural; Corinne Zara; Brian Godman
Journal:  Front Pharmacol       Date:  2016-07-22       Impact factor: 5.810
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.